Acta Scientific Gastrointestinal Disorders (ASGIS)(ISSN: 2582-1091)

Research Article Volume 5 Issue 12

CDH1 Gene Expression Alterations in Prostate Cancer Cell Lines After DAC And TSA Applications

Evrim Suna Arikan Söylemez1*, Zafer Söylemez1, Muhsin Elmas2 and Müjgan Özdemir Erdoğan2

1Department of Medical Biology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey

2Department of Medical Genetic, Faculty of Medicine, Afyonkarahisar Health Sciences University, Turkey

*Corresponding Author: Evrim Suna Arikan Söylemez, Assistant Professor, Department of Medical Biology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey.

Received: October 18, 2022; Published: November 16, 2022


Cancer is characterized by genetic and epigenetic disorder by uncontrolled growth and deterioration of the behavior of normal cell division (proliferation) and spread to other tissues (metastasis). Genes that control the division patterns in cancer cells has been mutated or show anormal expression levels or profiles. Prostate cancer is formed by uncontrolled proliferation of cells in the prostate gland. The expression of one of the major intercellular epithelial cell adhesion protein, e-cadherin, mediates the epithelial cell-cell interactions through calcium-dependent homophilic interaction of its extracellular domain. However, a reduction or loss of membranous expression of e-cadherin protein has been reported in invasive cancer cells at their primary sites. In this study, DNA methyl transferase inhibitor [5-aza.2.deoxycytidine (DAC), an epigenetic modulating drug that can reverse DNA methylation] and histone acetyltransferase enzyme inhibitor (TSA: Trichostatin A) applied to prostate cell lines (LNCaP, PC3 ve DU145) to determine gene expression levels of CDH1. When the changes in CDH1 mRNA level were examined after incubation of DU145 cells with 48 h 2 μM DAC, 300 nm TSA and 42 h DAC + 6 h 300 nm TSA, significant upregulation was detected in gene expression compared to control in all three applications (P < 0,001). When changes in CDH1 mRNA level in PC3 cells were examined; significant upregulation was determined in 2 μM DAC application, while significant downregulation was determined in 500 nm TSA and 42sa DAC + 6 h 500 nm TSA applications (P < 0,001). When the changes in CDH1 mRNA level of LNCaP cells were examined, significant upregulation was determined in 1.8 μM DAC application, while significant downregulation was determined in 200 nm TSA and 42sa DAC + 6 h 200 nm TSA applications (P < 0,001).

As a result, prostate cancer cell lines may be an ideal medium for testing demethylation drugs, but it is uncertain whether CDH1 promoter methylation is a specific mechanism for e-cadherin suppression. Therefore, in some cases, failure of the clinical activity of demethylation agents can be observed in the presence of methylated genes.

Keywords: e-cadherin; Prostate Cancer; DU145; LNCaP; PC3; Cell Line


  1. Momparler R L and V Bovenzi. “DNA methylation and cancer”. Journal of Cellular Physiology2 (2000): 145-154.
  2. Esteller Manel. “Cancer epigenomics: DNA methylomes and histone-modification maps”. Nature Reviews Genetics4 (2007): 286-298.
  3. Melki John R and Susan J Clark. “DNA methylation changes in leukaemia”. Seminars in Cancer Biology5 (2002): 347-357.
  4. Bird A P and A P Wolffe. “Methylation-induced repression--belts, braces and chromatin”. Cell5 (1999): 451-454.
  5. Placek Katarzyna., et al. “Epigenetic reprogramming of immune cells in injury, repair and resolution”. The Journal of clinical investigation8 (2019): 2994-3005.
  6. Jaenisch Rudolf and Adrian Bird. “Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals”. Nature Genetics 33 (2003): 245-254.
  7. Umbas R., et al. “Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer”. Cancer Research14 (1994): 3929-3933.
  8. Ross J S., et al. “E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder”. Human Pathology9 (1995): 940-944.
  9. Richmond P J., et al. “Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival”. Cancer Research15 (1997): 3189-3193.
  10. Gamallo C., et al. “Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma”. The American Journal of Pathology4 (1993): 987-993.
  11. Lipponen P., et al. “Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer”. The Journal of Pathology 174,2 (1994): 101-109.
  12. Verdin Eric., et al. “Class II histone deacetylases: versatile regulators”. Trends in Genetics : TIG5 (2003): 286-293.
  13. Müller Berit Maria., et al. “Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression”. BMC Cancer 13 (2013): 215.
  14. Yoshida, M., et al. “Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A”. The Journal of Biological Chemistry28 (1990): 17174-17179.
  15. Tan Jiahuai., et al. “Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents”. Journal of Hematology and Oncology5 (2010).
  16. Pfaffl Michael W., et al. “Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR”. Nucleic Acids Research9 (2002): e36.
  17. Sandoval Juan and Manel Esteller. “Cancer epigenomics: beyond genomics”. Current Opinion in Genetics and Development1 (2012): 50-55.
  18. Dobosy Joseph R., et al. “The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia”. The Journal of Urology3 (2007): 822-831.
  19. Berger Shelley L. “The complex language of chromatin regulation during transcription”. Nature7143 (2007): 407-412.
  20. Jerónimo, Carmen., et al. “Epigenetics in prostate cancer: biologic and clinical relevance”. European Urology4 (2011): 753-766.
  21. Tsai Hsing-Chen and Stephen B Baylin. “Cancer epigenetics: linking basic biology to clinical medicine”. Cell Research3 (2011): 502-517.
  22. Heyn Holger and Manel Esteller. “DNA methylation profiling in the clinic: applications and challenges”. Nature Reviews. Genetics10 (2012): 679-692.
  23. Henrique Rui., et al. “Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer”. Journal of molecular medicine (Berlin, Germany)11 (2006): 911-918.
  24. Costa Vera L., et al. “TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers”. Epigenetics9 (2011): 1120-1130.
  25. Machado J C., et al. “E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma”. Oncogene12 (2001): 1525-1528.
  26. Tamura G., et al. “E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas”. Journal of the National Cancer Institute7 (2000): 569-573.
  27. Oue Naohide., et al. “Distinct promoter hypermethylation of p16INK4a, CDH1 and RAR-beta in intestinal, diffuse-adherent and diffuse-scattered type gastric carcinomas”. The Journal of Pathology1 (2002): 55-59.
  28. Baylin Stephen B. “DNA methylation and gene silencing in cancer”. Nature Clinical Practice. Oncology1 (2005): S4-11.
  29. Qin Weihua., et al. “Regulation of DNA methyltransferase 1 by interactions and modifications”. Nucleus (Austin, Tex.)5 (2011): 392-402.


Citation: Evrim Suna Arikan Söylemez., et al.CDH1 Gene Expression Alterations in Prostate Cancer Cell Lines After DAC And TSA Applications". Acta Scientific Gastrointestinal Disorders 5.12 (2022): 08-15.


Copyright: © 2022 Evrim Suna Arikan Söylemez., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate35%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US